

BEST AVAILABLE COPY

MAY. 23. 2006 4:26PM

312 616 5700

NO. 2426 P. 5

Application No. 10/084,813

Reply to Office Action

CLAIM AMENDMENTS

1.-20. (Cancelled)

21. (Previously Presented) A polypeptide comprising an amino acid sequence selected from the group consisting of QWDFGNTMCQLLTGLYFIGFFS (SEQ ID NO: 12), SQYQFWKNFQTLKIVILG (SEQ ID NO: 13), APYNIVLLLNTFQEFFGLNNCS (SEQ ID NO: 14), YAFVGEKFRNYLLVFFQK (SEQ ID NO: 15), and SEQ ID NOs: 12-15 with up to 6 conservative or neutral amino acid substitutions, wherein the polypeptide binds with HIV gp120 under physiological conditions and comprises less than 100 contiguous amino acid residues that are identical to the amino acid sequence of the human CCR5 chemokine receptor.

22.-59. (Cancelled)

60. (Previously Presented) A composition comprising the polypeptide of claim 21 and a carrier.

61.-69. (Cancelled)

70. (Previously Presented) The polypeptide of claim 21, wherein the polypeptide comprises QWDFGNTMCQLLTGLYFIGFFS (SEQ ID NO: 12).

71. (Previously Presented) The polypeptide of claim 21, wherein the polypeptide comprises SQYQFWKNFQTLKIVILG (SEQ ID NO: 13).

72. (Previously Presented) The polypeptide of claim 21, wherein the polypeptide comprises APYNIVLLLNTFQEFFGLNNCS (SEQ ID NO: 14).

73. (Previously Presented) The polypeptide of claim 21, wherein the polypeptide comprises YAFVGEKFRNYLLVFFQK (SEQ ID NO: 15).

74. (Previously Presented) The polypeptide of claim 21, wherein the polypeptide comprises QWDFGNTMCQLLTGLYFIGFFS (SEQ ID NO: 12) with up to 6 conservative or neutral amino acid substitutions.

BEST AVAILABLE COPY

MAY. 23. 2006 | 4:27PM 312 616 5700

NO. 2426 P. 6

Application No. 10/084,813

Reply to Office Action

75. (Previously Presented) The polypeptide of claim 21, wherein the polypeptide comprises SQYQFWKNFQTLKIVILG (SEQ ID NO: 13) with up to 6 conservative or neutral amino acid substitutions.

76. (Previously Presented) The polypeptide of claim 21, wherein the polypeptide comprises APYNIVLLLNTFQEFGLNCS (SEQ ID NO: 14) with up to 6 conservative or neutral amino acid substitutions.

77. (Previously Presented) The polypeptide of claim 21, wherein the polypeptide comprises YAFVGEKFRNYLLVFFQK (SEQ ID NO: 15) with up to 6 conservative or neutral amino acid substitutions.

78. (Previously Presented) A composition comprising the polypeptide of claim 70 and a carrier.

79. (Previously Presented) A composition comprising the polypeptide of claim 71 and a carrier.

80. (Previously Presented) A composition comprising the polypeptide of claim 72 and a carrier.

81. (Previously Presented) A composition comprising the polypeptide of claim 73 and a carrier.

82. (Previously Presented) A composition comprising the polypeptide of claim 74 and a carrier.

83. (Previously Presented) A composition comprising the polypeptide of claim 75 and a carrier.

84. (Previously Presented) A composition comprising the polypeptide of claim 76 and a carrier.

85. (Previously Presented) A composition comprising the polypeptide of claim 77 and a carrier.

86. (New) The polypeptide of claim 74, wherein the polypeptide comprises SEQ ID NO: 12 with up to one conservative or neutral amino acid substitution.

BEST AVAILABLE COPY

MAY. 23. 2006 | 4:27PM 312 616 5700

NO. 2426 P. 7

Application No. 10/084,813

Reply to Office Action

87. (New) The polypeptide of claim 75, wherein the polypeptide comprises SEQ ID NO: 13 with up to one conservative or neutral amino acid substitution.

88. (New) The polypeptide of claim 76, wherein the polypeptide comprises SEQ ID NO: 14 with up to one conservative or neutral amino acid substitution.

89. (New) The polypeptide of claim 77, wherein the polypeptide comprises SEQ ID NO: 15 with up to one conservative or neutral amino acid substitution.